BR112021018817A2 - Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade - Google Patents
Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidadeInfo
- Publication number
- BR112021018817A2 BR112021018817A2 BR112021018817A BR112021018817A BR112021018817A2 BR 112021018817 A2 BR112021018817 A2 BR 112021018817A2 BR 112021018817 A BR112021018817 A BR 112021018817A BR 112021018817 A BR112021018817 A BR 112021018817A BR 112021018817 A2 BR112021018817 A2 BR 112021018817A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- weight
- peptides
- proteins
- small molecules
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000035699 permeability Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 150000003384 small molecules Chemical class 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- -1 fatty acid triglycerides Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade. a presente invenção refere-se a uma divulgação dirigida para uma formulação farmacêutica, destinada à distribuição oral de moléculas pouco permeáveis sintéticas ou naturais, ou sais/solvatos das mesmas tendo uma atividade terapêutica. a formulação farmacêutica pode incluir uma molécula pouco permeável sintética ou natural, ou sal ou solvato da mesma em uma quantidade de 0,01-10 % em peso do peso total da formulação; uma fase lipofílica compreendendo triglicerídeos de ácidos graxos em uma quantidade de 50-80 % em peso do peso total da formulação; e pelo menos um tensoativo lipofílico compreendendo ésteres parciais de poliol e ácidos graxos, em uma quantidade de cerca de 10-50 % em peso do peso total da formulação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962832508P | 2019-04-11 | 2019-04-11 | |
PCT/US2020/027801 WO2020210723A1 (en) | 2019-04-11 | 2020-04-10 | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021018817A2 true BR112021018817A2 (pt) | 2021-11-23 |
Family
ID=70476554
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021018817A BR112021018817A2 (pt) | 2019-04-11 | 2020-04-10 | Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade |
BR112021020287A BR112021020287A2 (pt) | 2019-04-11 | 2020-04-10 | Formulação para distribuição oral de proteínas, peptídeos e pequenas moléculas com pouca permeabilidade |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021020287A BR112021020287A2 (pt) | 2019-04-11 | 2020-04-10 | Formulação para distribuição oral de proteínas, peptídeos e pequenas moléculas com pouca permeabilidade |
Country Status (16)
Country | Link |
---|---|
US (3) | US11185589B2 (pt) |
EP (2) | EP3952899A1 (pt) |
JP (2) | JP2022526833A (pt) |
KR (2) | KR20210151187A (pt) |
CN (2) | CN113784722A (pt) |
AR (1) | AR118654A1 (pt) |
AU (2) | AU2020272059A1 (pt) |
BR (2) | BR112021018817A2 (pt) |
CA (2) | CA3134550A1 (pt) |
CO (2) | CO2021012462A2 (pt) |
EA (2) | EA202192793A1 (pt) |
IL (2) | IL287084A (pt) |
MX (2) | MX2021012354A (pt) |
SG (2) | SG11202110546UA (pt) |
WO (2) | WO2020210722A1 (pt) |
ZA (1) | ZA202108909B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8903804D0 (en) | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
JPH08507078A (ja) * | 1993-02-17 | 1996-07-30 | スミスクライン・ビーチャム・コーポレイション | 治療用ペプチド含有のミクロエマルジョン |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
DE60206889T2 (de) | 2001-02-27 | 2006-07-27 | Astrazeneca Ab | Pharmazeutische formulierung enthaltend bicalutamid |
CZ20033341A3 (cs) * | 2001-06-21 | 2004-10-13 | Pfizeráproductsáinc | Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru |
JP2005515197A (ja) * | 2001-12-03 | 2005-05-26 | ドー バイオファーマ インコーポレイテッド | 安定化された逆ミセル組成物およびその使用 |
AU2003237255B8 (en) | 2002-06-05 | 2010-01-07 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US20050249802A1 (en) | 2004-05-06 | 2005-11-10 | The Procter & Gamble Company | Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients |
CN101048137A (zh) * | 2004-10-29 | 2007-10-03 | 诺瓦提斯公司 | 可自发分散的药物组合物 |
KR20070084531A (ko) * | 2004-11-24 | 2007-08-24 | 머크 앤드 캄파니 인코포레이티드 | 치환된 아미드의 경구 투여용 액체 및 반고체 약제학적제형 |
US20080014274A1 (en) | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
CA2662748A1 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
AU2008244523B2 (en) * | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US8323695B2 (en) | 2007-08-13 | 2012-12-04 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
WO2009040034A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
CN102892411B (zh) * | 2009-12-18 | 2015-01-21 | 恩多提斯药业公司 | 含有合成的低聚糖的药物口服剂型 |
US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
WO2013173687A1 (en) * | 2012-05-18 | 2013-11-21 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
CN105007891B (zh) | 2013-02-28 | 2018-01-16 | 辉瑞公司 | 新液体组合物的增强的稳定性 |
US8859623B1 (en) | 2013-11-14 | 2014-10-14 | Paragon BioTeck, Inc. | Methods and compositions of stable phenylephrine formulations |
EP3142699A4 (en) * | 2014-05-16 | 2017-11-22 | Salk Institute for Biological Studies | Compositions and methods for treating metabolic disorders |
CA3001337C (en) | 2015-10-09 | 2023-12-12 | Reckitt Benckiser Llc | Pharmaceutical formulation |
EP3362048A4 (en) * | 2015-10-14 | 2019-06-05 | Pharcon Inc. | COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS |
-
2020
- 2020-04-10 CA CA3134550A patent/CA3134550A1/en active Pending
- 2020-04-10 AU AU2020272059A patent/AU2020272059A1/en active Pending
- 2020-04-10 WO PCT/US2020/027800 patent/WO2020210722A1/en active Application Filing
- 2020-04-10 EP EP20722945.1A patent/EP3952899A1/en active Pending
- 2020-04-10 JP JP2021559862A patent/JP2022526833A/ja active Pending
- 2020-04-10 US US16/845,830 patent/US11185589B2/en active Active
- 2020-04-10 MX MX2021012354A patent/MX2021012354A/es unknown
- 2020-04-10 KR KR1020217036828A patent/KR20210151187A/ko active Search and Examination
- 2020-04-10 EP EP20723680.3A patent/EP3952900A1/en active Pending
- 2020-04-10 SG SG11202110546UA patent/SG11202110546UA/en unknown
- 2020-04-10 CA CA3136485A patent/CA3136485A1/en active Pending
- 2020-04-10 CN CN202080027875.4A patent/CN113784722A/zh active Pending
- 2020-04-10 EA EA202192793A patent/EA202192793A1/ru unknown
- 2020-04-10 MX MX2021012356A patent/MX2021012356A/es unknown
- 2020-04-10 SG SG11202111251SA patent/SG11202111251SA/en unknown
- 2020-04-10 KR KR1020217036823A patent/KR20210151185A/ko unknown
- 2020-04-10 EA EA202192792A patent/EA202192792A1/ru unknown
- 2020-04-10 WO PCT/US2020/027801 patent/WO2020210723A1/en active Application Filing
- 2020-04-10 BR BR112021018817A patent/BR112021018817A2/pt unknown
- 2020-04-10 BR BR112021020287A patent/BR112021020287A2/pt unknown
- 2020-04-10 JP JP2021560705A patent/JP2022526196A/ja active Pending
- 2020-04-10 AU AU2020270985A patent/AU2020270985A1/en active Pending
- 2020-04-10 US US17/602,915 patent/US20220249468A1/en active Pending
- 2020-04-10 CN CN202080042824.9A patent/CN113966223A/zh active Pending
- 2020-04-13 AR ARP200101031A patent/AR118654A1/es unknown
-
2021
- 2021-09-23 CO CONC2021/0012462A patent/CO2021012462A2/es unknown
- 2021-10-07 IL IL287084A patent/IL287084A/en unknown
- 2021-10-10 IL IL287131A patent/IL287131A/en unknown
- 2021-11-04 CO CONC2021/0014899A patent/CO2021014899A2/es unknown
- 2021-11-10 ZA ZA2021/08909A patent/ZA202108909B/en unknown
- 2021-11-29 US US17/536,452 patent/US20220143188A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA202192792A1 (ru) | 2022-01-11 |
BR112021020287A2 (pt) | 2021-12-14 |
AU2020272059A1 (en) | 2021-12-09 |
ZA202108909B (en) | 2022-07-27 |
CN113784722A (zh) | 2021-12-10 |
CA3136485A1 (en) | 2020-10-15 |
AR118654A1 (es) | 2021-10-20 |
CO2021014899A2 (es) | 2021-11-19 |
KR20210151187A (ko) | 2021-12-13 |
SG11202111251SA (en) | 2021-11-29 |
MX2021012354A (es) | 2021-10-22 |
JP2022526196A (ja) | 2022-05-23 |
IL287131A (en) | 2021-12-01 |
WO2020210722A1 (en) | 2020-10-15 |
SG11202110546UA (en) | 2021-10-28 |
US20200323985A1 (en) | 2020-10-15 |
US20220143188A1 (en) | 2022-05-12 |
US11185589B2 (en) | 2021-11-30 |
KR20210151185A (ko) | 2021-12-13 |
IL287084A (en) | 2021-12-01 |
MX2021012356A (es) | 2021-11-04 |
EP3952899A1 (en) | 2022-02-16 |
AU2020270985A1 (en) | 2021-12-09 |
CO2021012462A2 (es) | 2021-09-30 |
CN113966223A (zh) | 2022-01-21 |
JP2022526833A (ja) | 2022-05-26 |
CA3134550A1 (en) | 2020-10-15 |
TW202103726A (zh) | 2021-02-01 |
US20220249468A1 (en) | 2022-08-11 |
EP3952900A1 (en) | 2022-02-16 |
EA202192793A1 (ru) | 2022-01-12 |
WO2020210723A1 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Timper et al. | GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function | |
Perry et al. | Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas | |
Guiraud et al. | Pharmacological advances for treatment in Duchenne muscular dystrophy | |
CN106456703A (zh) | 铁调素模拟肽及其用途 | |
ES2733639T3 (es) | Composiciones de insulina de acción rápida | |
Bohanon et al. | Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis | |
Zappa Villar et al. | Intracerebroventricular streptozotocin induces impaired Barnes maze spatial memory and reduces astrocyte branching in the CA1 and CA3 hippocampal regions | |
ES2441065T3 (es) | Uso de la deferiprona y métodos para tratar y/o prevenir la ataxia de Friedreich resultante del mal manejo intracelular de hierro | |
Yang et al. | Small-molecule TrkB agonist 7, 8-dihydroxyflavone reverses cognitive and synaptic plasticity deficits in a rat model of schizophrenia | |
BR112016003358A2 (pt) | método para aumentar a expressão de proteínas codificadas por rna | |
UY38068A (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
Lau et al. | Apical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in the intestinal epithelium | |
ES2822942T3 (es) | Formulaciones de productos biológicos para instilación intravesical | |
Ono et al. | Imipramine protects mouse hippocampus against tunicamycin-induced cell death | |
BR112018012641A2 (pt) | molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição. | |
Hooshmandi et al. | CEPO-Fc (an EPO derivative) protects hippocampus against Aβ-induced memory deterioration: a behavioral and molecular study in a rat model of Aβ toxicity | |
AR114325A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
UY38067A (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
BR112021018817A2 (pt) | Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade | |
KR20200022435A (ko) | 펩타이드 조성물 및 관련된 방법 | |
Tang et al. | Role of silent information regulator 1 in the protective effect of hydrogen sulfide on homocysteine-induced cognitive dysfunction: involving reduction of hippocampal ER stress | |
US20200360328A1 (en) | Compositions and methods for treating cancer | |
JP2018506508A (ja) | がんおよび血管形成関連疾患を処置するためのCD44v6由来環状ペプチド | |
BR112012015016A8 (pt) | Formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação | |
Kersanté et al. | Anti-opioid effects of neuropeptide FF receptors in the ventral tegmental area |